WHO Warns Global Emergency Cholera Vaccine Stockpile Is Depleted

The World Health Organization (WHO) and the International Coordinating Group (ICG) on Vaccine Provision have issued an urgent global warning, revealing that the international emergency stockpile of oral cholera vaccines (OCV) has been depleted to zero available doses. The unprecedented exhaustion of emergency reserves leaves international responders without buffer supplies as active, life-threatening outbreaks sweep across 24 countries simultaneously.

Over the past twelve months, global demand for oral cholera vaccines reached more than double the world's total manufacturing output. Severe humanitarian emergencies—most acutely in conflict-ravaged Sudan, flood-devastated regions of Ethiopia, and gang-blockaded communities in Haiti—have generated massive infection spikes that consumed shipments faster than pharmaceutical manufacturers could produce them.

Zero Reserve Doses Amid Concurrent Global Outbreaks

Cholera, an acute diarrheal infection caused by ingestion of water or food contaminated with the bacterium Vibrio cholerae, can kill within hours if untreated. While clean drinking water and sanitation remain the ultimate long-term solutions, oral vaccines represent the most effective rapid intervention to prevent mass fatalities in displaced populations and refugee settlements.

Due to the persistent scarcity, the ICG was forced to suspend its standard two-dose regimen in late 2022, shifting exclusively to a single-dose strategy to stretch finite stocks. While a single dose confers immediate immunity, the protection wanes much faster, leaving vulnerable populations susceptible to secondary waves without booster follow-ups.

“The global cholera vaccine stockpile is completely exhausted. We are seeing unprecedented demand driven by conflict, floods, and droughts, leaving millions vulnerable to preventable waterborne death.” — Dr. Philippe Barboza, WHO Cholera Team Lead

Climate Shocks, Armed Conflict, and Dose Rationing

International health agencies, alongside Gavi, the Vaccine Alliance, and UNICEF, are urging global pharmaceutical manufacturers to scale up biomanufacturing facilities and simplify antigen formulations to expand yield. However, new production lines are not projected to enter commercial operation until next year, creating a perilous operational gap for ongoing containment campaigns.

The WHO called upon international donor governments to urgently release emergency financing for water, sanitation, and hygiene (WASH) infrastructure in frontline hotspots. Officials warned that without immediate investments in basic clean water access, the absence of vaccine reserves could precipitate catastrophic mortality across vulnerable displacement camps.

Sources

• World Health Organization
• Gavi The Vaccine Alliance